Iterum Therapeutics (NASDAQ: ITRM)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.040 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Iterum Therapeutics (NASDAQ: ITRM) through any online brokerage.
Other companies in Iterum Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), Cumberland (NASDAQ:CPIX), Cocrystal Pharma (NASDAQ:COCP), Ocuphire Pharma (NASDAQ:OCUP) and Lipocine (NASDAQ:LPCN).
The latest price target for Iterum Therapeutics (NASDAQ: ITRM) was reported by Gabelli & Co. on Tuesday, July 27, 2021. The analyst firm set a price target for 0.00 expecting ITRM to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Iterum Therapeutics (NASDAQ: ITRM) is $0.2221 last updated Today at August 17, 2022, 7:54 PM UTC.
There are no upcoming dividends for Iterum Therapeutics.
Iterum Therapeutics’s Q3 earnings are confirmed for Friday, November 11, 2022.
The stock split for ITRM was announced on Tuesday, August 16, 2022. The date this stock split will start trading, also known as the ex-date, will be on Thursday, August 18, 2022.
Iterum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.